• Rein Therapeutics posted a press release stating its Phase 2 RENEW trial of inhaled LTI-03 in idiopathic pulmonary fibrosis is enrolling across five countries.
• The randomized, placebo-controlled study targets about 120 patients.
• Initial topline data remain slated for 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210800PRIMZONEFULLFEED9764907) on July 21, 2026, and is solely responsible for the information contained therein.